Chimeric antigen receptor T-cell therapy - Hunan Zhaotai Yongren Biotech/Hunan Yongren Medical Innovation

Drug Profile

Chimeric antigen receptor T-cell therapy - Hunan Zhaotai Yongren Biotech/Hunan Yongren Medical Innovation

Alternative Names: Z-CTLs; Zeushield Cytotoxic T Lymphocytes

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hunan Yongren Medical Innovation; Hunan Zhaotai Yongren Biotech
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD274 antigen inhibitors; CD80 antigen inhibitors; CD86 antigen inhibitors; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 12 Feb 2017 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT03060343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top